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ABSTRACT: Viral pathogenesis in the infected cell is a balance between
antiviral responses and subversion of host-cell processes. Many viral proteins
speciﬁcally interact with host-cell proteins to promote virus biology.
Understanding these interactions can lead to knowledge gains about
infection and provide potential targets for antiviral therapy. One such virus
is Ebola, which has profound consequences for human health and causes viral
hemorrhagic fever where case fatality rates can approach 90%. The Ebola
virus VP24 protein plays a critical role in the evasion of the host immune
response and is likely to interact with multiple cellular proteins. To map
these interactions and better understand the potential functions of VP24,
label-free quantitative proteomics was used to identify cellular proteins that
had a high probability of forming the VP24 cellular interactome. Several
known interactions were conﬁrmed, thus placing conﬁdence in the
technique, but new interactions were also discovered including one with ATP1A1, which is involved in osmoregulation and
cell signaling. Disrupting the activity of ATP1A1 in Ebola-virus-infected cells with a small molecule inhibitor resulted in a
decrease in progeny virus, thus illustrating how quantitative proteomics can be used to identify potential therapeutic targets.
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■ INTRODUCTION
Ebola virus causes severe hemorrhagic fever in humans and
nonhumans primates. Because of the high mortality rate,
potential transmission from person-to-person contact, and the
lack of approved vaccines or antiviral therapies, Ebola viruses
are classiﬁed as hazard group 4 pathogens by the Advisory
Committee on Dangerous Pathogens (ACDP). The Ebolavirus
genus is one of three genera of the family Filoviridae. Currently,
this genus is composed of ﬁve alternative species of the Ebola
virus, which are associated with diﬀerent pathogenicity and case
fatality rates. Zaire Ebola virus (EBOV) is the most pathogenic
for humans and causes sporadic outbreaks with fatality rates
reaching up to 90%, while Reston Ebola virus (RESTV) is not
pathogenic for humans. However, RESTV can cause viral
hemorrhagic fever in nonhuman primates and illustrates the
potential zoonotic threat of Ebola virus.1−3 Ebola virus
outbreaks occur irregularly, with the most recent outbreak
occurring in West Africa in 2014, with fatality rates currently
over 60%.
Ebola virus is an enveloped nonsegmented negative single-
stranded RNA virus with a genome of 19kb in length consisting
of seven genes encoding eight proteins: nucleoprotein (NP),
virion protein (VP) 35, VP40, glycoprotein (GP), VP30, VP24,
and the RNA-dependent RNA polymerase (L). The combina-
tion and action of these gene products and their interactions
with the host cell cause the severe hemorrhagic fever. One of
the proteins thought to contribute to disease pathology is VP24
and may be a major factor in virulence.4 This protein is
considered a secondary matrix protein as only a small amount
of VP24 is incorporated into viral particles. However, VP24 has
aﬃnity for the plasma membrane and is associated with the
envelope of the virion. VP24 has been shown to have several
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functions, including an involvement in viral nucleocapsid
formation and the regulation of replication.5,6
Critically, VP24 is also involved in modulation of the host
response to infection through evasion of the host immune
response. VP24 may disrupt interferon signaling by binding to
karyopherin-α (KNP-α),7 which blocks the nuclear accumu-
lation of tyrosine-phosphorylated STAT1 (PY-STAT).8 STAT1
is a major signaling molecule involved in initiating the antiviral
response.9 Nuclear translocation of STAT1 is essential for
transcriptional activation of numerous interferon responsive
genes. VP24 can also inhibit IFN-α/β- and IFN-γ-induced gene
expression.10 The mechanism of action through which VP24
modulates the immune response is unknown. However, other
work suggested that VP24 may be structurally similar to
importin-α/β and exportin.11 Thus, VP24 may be involved in
the mimicry of host transporter/cargo interactions.11,12
Mutations in VP24 have been linked to the adaptation of
Zaire Ebola virus in mice and guinea pigs to produce lethal
disease.13−15
Therefore, VP24 may form critical protein−protein inter-
actions with host-cell proteins to modulate host-cell pathways;
this is the case of the interaction of VP24 with karyopherin,
which is required for the inhibition of the interferon-signaling
pathway. Elucidating these interactions in detail would provide
a deeper understanding of Ebola virus infection and also
potentially present antiviral chemo-therapeutic targets to
disrupt virus biology.
To determine which cellular proteins or complexes interact
with VP24 and to predict function, we have used high-aﬃnity
puriﬁcation coupled to a label-free mass-spectrometry-based
approach. Using conservative selection criteria, approximately
50 cellular proteins were identiﬁed that had a high probability
of interacting with VP24. Some of the candidate proteins had
been identiﬁed in previous analyses, conﬁrming that our
approach was able to identify known interactions, thus
increasing conﬁdence that the analysis was capable of
identifying new cellular proteins in the same experiment. One
of the novel hits identiﬁed was sodium/potassium-transporting
ATPase subunit alpha-1 (ATP1A1). This enzyme can be
inhibited by the small-molecule inhibitor ouabain, which is used
in the treatment of heart failure. We used this drug in
experiments to inhibit the function of ATP1A1 in cells infected
with Ebola virus. The data indicated that progeny virus
decreased in treated infected cells compared with untreated
infected cells.
■ EXPERIMENTAL PROCEDURES
EGFP-VP24 and VP24-EGFP Construction
Codon-optimized (for expression in human cells) cDNA
sequence encoding Zaire EBOV Mayinga Strain 1976 VP24
protein (NCBI reference sequence number: NP_066250.1)
was cloned into the pEGFP-C1 and pEGFP-N1 vectors to
generate Zaire EBOV VP24 with C-terminal EGFP tag and N-
terminal EGFP tag; the plasmid sequences were conﬁrmed by
sequencing.
Cell Culture and Transfections
HEK 293T cells were grown in Dulbecco’s modiﬁed Eagle’s
medium (DMEM; Sigma-Aldrich) supplemented with 10%
fetal bovine serum (FBS; Sigma-Aldrich) and 1% penicillin-
streptomycin (Sigma-Aldrich) at 37 °C with 5% CO2. To
transfect 293T cells, two 145 cm2 dishes were seeded with 4 ×
106 cells 24 h prior to calcium phosphate transfection with 25.6
μg of plasmid DNA encoding EGFP, EGFP-VP24, and VP24-
EGFP, respectively. After 24 h post-transfection the cells were
harvested, lysed, and immunoprecipitated using a GFP-Trap
(Chromotek).
EGFP Coimmunoprecipitations
EGFP-VP24, VP24-EGFP, and EGFP immunoprecipitations
were performed using a GFP-Trap_A (Chromotek), and cell
pellet was resuspended in 200 μL of lysis buﬀer (10 mM Tris/
Cl pH 7.5; 150 mM NaCl; 0.5 mM EDTA; 0.5%NP40)
supplemented with Halt Protease Inhibitor Cocktail EDTA-
Free (Thermo Scientiﬁc) and incubated for 30 min on ice. The
lysate was clariﬁed by centrifugation at 14 000g and diluted ﬁve-
fold with dilution buﬀer (10 mM Tris/Cl pH 7.5; 150 mM
NaCl; 0.5 mM EDTA) supplemented with Halt Protease
Inhibitor Cocktail EDTA-Free (Thermo Scientiﬁc). The GFP-
Trap agarose beads were equilibrated with ice-cold dilution
buﬀer supplemented with Halt Protease Inhibitor Cocktail
EDTA-Free (Thermo Scientiﬁc) and then incubated with
diluted cell lysate overnight at 4 °C on a rotator, followed by
centrifugation at 2700g for 2 min. The bead pellet was washed
two times with wash buﬀer (10 mM Tris/Cl pH 7.5; 150 mM
NaCl; 0.5 mM EDTA) supplemented with Halt Protease
Inhibitor Cocktail EDTA-Free (Thermo Scientiﬁc). After the
removal of wash buﬀer the beads were resuspended with 25 μL
of elution buﬀer (200 mM Glycine pH 2.5) and incubated for
10 min at room temperature in a thermal shaker to elute bound
proteins; the beads were then collected by centrifugation, and
the eluted proteins were transferred to a 1.5 mL centrifuge
tube. This step was repeated four times to ensure the maximum
elution and all of the eluates were combined; 10 μL of Tris-base
buﬀer (pH 10.4) was added to neutralize the eluate.
Immunoprecipitated samples were then analyzed using label-
free mass spectrometry.
Reverse Coimmunoprecipitation
Immunoprecipitations for Karyopherin α6 and Lamin B1 were
performed using the immobilized recombinant protein G resin
(Generon) and speciﬁc antibodies against karyopherin α6 (E-
11) (Santa Cruz Biotechnology; sc-390055) and Lamin B1
(ZL-5) (Santa Cruz Biotechnology; sc-56145). cell pellets were
incubated for 30 min on ice with 200 μL of lysis buﬀer; the
lysate was clariﬁed by centrifugation and diluted ﬁve-fold with
dilution buﬀer prior to adding 2 μg of the primary antibody and
then incubated at 4 °C on a rotator for 2 h. The protein G resin
(Generon) was equilibrated with ice-cold dilution buﬀer and
then incubated at 4 °C on a rotator with diluted cell lysate
containing the antibody overnight at 4 °C on a rotator,
followed by centrifugation at 2700g for 2 min to remove
nonbounds. The wash and elution steps were preformed as
previously described in GFP coimmunoprecipitation.
Label-Free Mass Spectrometry
Eluted samples were diluted two-fold with 25 mM ammonium
bicarbonate. Rapigest (Waters) was added to a ﬁnal
concentration of 0.05% (w/v), and the sample was heated to
80 °C for 10 min. Proteins were reduced with 3 mM
dithiothreitol (Sigma) at 60 °C for 10 min, then alkylated
with 9 mM iodoacetimide (Sigma) at room temperature for 30
min in the dark. Proteomic grade trypsin (Sigma) was added
(0.2 μg), and samples were incubated at 37 °C overnight. The
Rapigest was removed by adding TFA to a ﬁnal concentration
of 1% (v/v) and incubating at 37 °C for 2 h. Peptide samples
were centrifuged at 12 000g for 60 min (4 °C) to remove
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precipitated Rapigest. Each digest was concentrated and
desalted using C18 Stage tips (Thermo Scientiﬁc), then dried
down using a centrifugal vacuum concentrator (Jouan) and
resuspended in a 0.1% (v/v) TFA, 3% (v/v) acetonitrile
solution.
Peptide mixtures (2 μL) were analyzed by online nano ﬂow
liquid chromatography using the nanoACQUITY-nLC system
(Waters MS technologies, Manchester, U.K.) coupled to an
LTQ-Orbitrap Velos (Thermo Fisher Scientiﬁc, Bremen,
Germany) mass spectrometer equipped with the manufacturer’s
nanospray ion source. The analytical column (Nano ACQUITY
UPLCTM BEH130 C18 15 cm × 75 μm, 1.7 μm capillary
column) was maintained at 35 °C and a ﬂow-rate of 300nL/
min. The gradient consisted of 3−40% acetonitrile in 0.1%
formic acid for 50 min then a ramp of 40−85% acetonitrile in
0.1% formic acid for 3 min. Full-scan MS spectra (m/z range
300−2000) were acquired by the Orbitrap at a resolution of 30
000. Analysis was performed in data-dependent mode. The top-
20 most intense ions from MS1 scan (full MS) were selected
for tandem MS by collision-induced dissociation (CID), and all
product spectra were acquired in the LTQ ion trap.
Label-Free Analysis
Label-free quantitation was performed using MaxQuant (MQ)
software (version 1.3.0.5.) with its internal search engine
Andromeda. Precursor mass and fragment mass were searched
with mass tolerance of 6 ppm and 0.5 Da, respectively. All other
settings were default. The search included variable modiﬁca-
tions of methionine oxidation and N-terminal acetylation and
ﬁxed modiﬁcation of carbamidomethyl cysteine. Enzyme
speciﬁcity was set to trypsin, minimal peptide length was set
to seven amino acids, and a maximum of two mis-cleavages was
allowed. The false discovery rate (FDR) was set to 0.01 for
peptide and protein identiﬁcations. The Andromeda search
engine was conﬁgured for a database containing human
proteins (Uniprot release-2013_03) and VP24 GFP constructs
(56601 entries). The MQ software further included a decoy
database as well as containing common contaminants to
determine the FDR and to exclude false-positive hits due to
contamination by proteins from diﬀerent species. For LFQ
analysis, “multiplicity” was set to one. Feature matching
between raw ﬁles was enabled using a retention time window
of 2 min. “Discard unmodiﬁed counterpart peptides” was
unchecked. Only unmodiﬁed and unique peptides were utilized.
Averaged LFQ intensity values were used to calculate protein
ratios.
Bioinformatics Analysis
Label-free mass spectrometry results were processed and
analyzed using the Perseus software (MaxQuant); this software
was used to perform the statistical analysis and to diﬀerentiate
background proteins (those cellular proteins that interacted
with EGFP alone) from interacting proteins (those cellular
proteins that interacted with EGFP-VP24 or VP24-EGFP).
LFQ intensity values were analyzed using a T-Test. A volcano
plot graphic and a table were generated showing the statistical
signiﬁcant proteins, those proteins that had a high probability of
interacting with VP24. The String 9.05. program was used to
predict the protein−protein interactions of the statistically
signiﬁcant proteins and also to group proteins according
function.
Western Blot Analysis
Beads were then resuspended and boiled in 100 μL of 2× SDS-
sample buﬀer at 95° for 10 min to elute the bound proteins.
The beads were then collected by centrifugation, and SDS-
PAGE was preformed with the supernatant (elution faction).
10% SDS polyacrylamide gels were used to perform the SDS-
PAGE; then, gels were transferred to PVDF membranes
(Millipore) using a semidry transfer system. Transferred
membranes were blocked in 5% skimmed milk powder
dissolved in TBS-0.1% Tween (TBS-T) (50 mM Tris-HCl
(pH8.3), 150 mM NaCl, and 0.5% (v/v) Tween-20) buﬀer for
60 min at room temperature. Primary antibody was diluted
1:1000 in blocking buﬀer and then incubated at 4 °C overnight;
antibodies used against GFP (Santa Cruz Biotechnology; sc-
8334), karyopherin α6 (E-11) (Santa Cruz Biotechnology; sc-
390055), Lamin B1 (ZL-5) (Santa Cruz Biotechnology; sc-
56145), and Na+/K+-ATPase α (H-3) (Santa Cruz Biotechnol-
ogy; sc-48345) were from Santa Cruz, and anti-VDAC1/porin
antibody was from Abcam (Abcam; ab14734). After three
washes, blots were incubated with appropriate HRP secondary
antibody diluted in blocking buﬀer at a 1:2000 for 1 h at room
temperature. Blots were developed using enhanced chemilu-
minesence reagent (BioRad) and detected using a BioRad
Imaging system.
Virus Infection and Treatment with Inhibitor
MRC-5 human fetal lung cells (European Collection of Cell
Cultures; 05081101) were maintained in Leibovitz’s L-15
media (Invitrogen; 31415-086) supplemented with 10% fetal
bovine serum (Sigma; F9665). Media was removed from the
cell monolayers, and the cells were infected with Ebola Zaire
virus (strain ME718) at a multiplicity of infection of ∼0.1, with
virus left to adsorb for 1 h at 37 °C. ME718 was isolated during
an outbreak in October 1976 (WHO International Commis-
sion, 1978). It was sourced from an acute phase serum sample
obtained from a 42-year-old Belgian nun (Sister M.E.) who
became ill on September 23, 1976, in Yambuku, Equateur
Province Zaire. This strain is equivalent to the Mayinga strain,
as Sister M.E. nursed Sister Mayinga (who the strain is named
after) and most likely contracted her infection. Leibovitz’s L-15
media containing 2% fetal bovine serum was added, and the
infected cells were incubated at 37 °C for 1 h. In triplicate
ﬂasks, Ouabbain Octahydrate (Sigma; O3125) was added to
the media to a ﬁnal concentration of 20 nM; a further three
ﬂasks were left as an untreated control. At 24 and 48 h
postinfection, a sample of media from each ﬂask was added to
AVL inactivation buﬀer (Qiagen; 19073) prior to removal from
the Containment Level 4 (CL4) laboratory for nucleic acid
extraction. The QIAamp Viral RNA Mini Kit from Qiagen (cat.
no. 52904) was used for nucleic acid extraction, as this
facilitated transport of the nucleic acid samples from CL4 to
CL2. Following the extraction of viral RNA, the cDNA was
synthesized using speciﬁc primers against the gene encoding
the nucleoprotein of Zaire Ebola virus. The cDNA was
synthesized using the Thermo Script RT-PCR System from
Invitrogen (cat. no. 11146-024) following the manufacturer’s
instructions. PCR was performed with Paq5000 DNA polymer-
ase (Agilent Technologies) (data not shown). Finally, a qPCR
was performed to compare the RNA levels in the infected cells
treated and untreated with Ouabain experiment. This was
performed with the iTaq Universal SYBR Green Supermix
(BIO RAD).
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■ RESULTS
Expression of VP24 in 293T Cells
To obtain a more complete picture of the interaction partners
of VP24, we used quantitative proteomics coupled to an
immunoprecipitation strategy based on expressing VP24 as an
EGFP-fusion in human 293-T cells and utilizing a GFP-trap to
selectively precipitate the fusion protein and interacting
partners (Figure 1A). 293-T cells are derived from embryonic
kidney cells and were chosen due to their ability to sustain
Ebola virus replication, their high transfection eﬃciencies using
calcium-phosphate, and the well-annotated human databases
that aid with protein identiﬁcation and function assignment. To
identify interacting cellular partners speciﬁc for VP24, we used
label-free LC−MS/MS to analyze binding partners from cells
expressing either EGFP or the EGFP-VP24 or VP24-EGFP
fusion proteins. Subsequent comparison of the immunopreci-
pitated interacting partners from these conditions allowed the
identiﬁcation of cellular components that speciﬁcally bound to
the VP24 moiety within the EGFP/VP24 fusion protein. This
general approach has been shown to improve sensitivity and
allow discrimination of speciﬁc from nonspeciﬁc interactions
with the target protein16,17 and can be readily applied to the
analysis of the cellular interactomes of viral proteins.18−20
To identify cellular proteins that interact with VP24, we
cloned the gene encoding EGFP either 5′ or 3′ of a gene
encoding codon-optimized VP24 from a virus similar to the
Zaire EBOV, Mayinga Strain 1976, such that when the
construct was transfected in cells the EGFP moiety was
expressed as either an N- or C-terminal fusion of VP24,
respectively. In this way, we mitigated against potential
nonbinding to cellular targets caused by steric hindrance of
the EGFP moiety. Proteins were precipitated using the anti-
EGFP antibody, and both input (cell lysate) and eluted fraction
were compared using immunoﬂuoresence (Figure 1B) and
Western blot (Figure 1C). The data indicated that both EGFP-
VP24 and VP24-EGFP were expressed with high eﬃciency at
the expected molecular weight (∼55 kDa).
Identiﬁcation of the Potential Cellular Interacting Partners
of VP24
EGFP-VP24, VP24-EGFP, and EGFP were then overexpressed
in 293T cells, and the cellular binding partners were
immunoprecipitated using the GFP-trap. These proteins were
identiﬁed by mass spectrometry. To diﬀerentiate those cellular
proteins that formed speciﬁc interactions with VP24 versus
those proteins that interacted with EGFP or formed nonspeciﬁc
interactions with the binding matrix, we repeated the immune
precipitations and mass spectrometry ﬁve times. Approximately
600 cellular proteins were initially identiﬁed and quantiﬁed,
which represented both the speciﬁc and nonspeciﬁc inter-
actions. To diﬀerentiate between these possibilities, we took
several conservative processing steps. The 15 data sets were
analyzed by the Perseus software algorithm. Proteins identiﬁed
by a single peptide were removed, and a p value was set at
<0.01 for the t-test analysis, where theoretically only 1:100
proteins were misidentiﬁed. The data were then organized in
the form of volcano plots for EGFP-VP24 and VP24-EGFP
(Figure 2A,B, respectively). These show P values (−log10) for
conﬁdence in peptide identiﬁcation versus fold diﬀerence in
binding of a protein between the VP24 fusion protein and
EGFP only. Dots represent individual proteins. Those dots
inside the volcano plots represent proteins that did not
associate with VP24 with statistical signiﬁcance. Proteins that
had a binding ratio greater than 2 and were statistically
signiﬁcant are shown in the right-hand quadrant. For EGFP-
VP24 and VP24-EGFP, 48 and 51 proteins (Table 1),
Figure 1. Expression of VP24 in 293T cells. (A) Schematic
representation of the methodology used in this study. HEK 293T
cells were grown in DMEM supplemented with 10% FBD and 1%
penicillin-streptomycin at 37 °C with 5% CO2. Two 145 cm2 dishes
were seeded with 4 × 106 cells 24 h prior to calcium phosphate
transfection with 25.6 μg of plasmid DNA encoding EGFP, EGFP-
VP24, and VP24-EGFP, respectively. 24 h post-transfection the cells
were harvested, lysed, and immunoprecipitated using a GFP-Trap
(Chromotek). Label-free mass spectrometry analysis on the eluted
samples was then carried out. (B) Expression of VP24-EGFP, EGFP-
VP24, and EGFP in 293T cells was conﬁrmed by immunoﬂuorescence
using confocal microscopy and DAPI (blue) to counterstain the
nucleus; the panels show that expression of two constructs were
similar (however, EGFP-VP24 shows a higher expression than VP24-
EGFP) and that approximately 50% of cells were transfected. (C)
Analysis of the pull-down products using a Western blot conﬁrm the
presence of EGFP-VP24, VP24-EGFP, and EGFP with the expected
molecular weight, conﬁrming the expression of these proteins in 293T
cells.
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respectively, were identiﬁed as interacting with statistical
signiﬁcance. Both fusion proteins had 40 proteins identiﬁed
in common; 8 proteins were unique for EGFP-VP24 and 11
proteins were unique for VP24-EGFP. A map of these protein−
protein interactions was performed using the String Algorithm
(version 9.05) and is presented in Figure 3.
Cellular proteins that had a higher statistical likelihood of
associating with VP24 included importin subunit alpha 1 and 6
(karyopherin-α1 and karyopherin-α6), lamin B1, VDAC-1, and
ATP1A1. Importin α1 has been previously shown to interact
with VP248 and therefore indicated that our approach identiﬁed
known interactions and increased conﬁdence in the analysis of
cellular proteins found in the same experiment. Comparison of
proteins identiﬁed as interacting with VP24 and their
abundance in an average human cell (data taken from PaxDb:
Protein Abundance Across Organisms database) (Table 1)
indicated that the likelihood of binding was not proportional to
their abundance in a cell, thus increasing conﬁdence that the
amount of binding was not merely a reﬂection of overall
protein abundance.
Figure 2. Volcano plot representing results of the label-free pull-down of EGFP-VP24 (A) or VP24-EGFP (B) versus the control EGFP performed
in triplicate. For any potential protein interaction partner with VP24, the value of its abundance coimmunoprecipitated with EGFP-VP24 or VP24-
EGFP was compared with the value of coimmunoprecipitated with EGFP alone. The logarithmic ratio of protein intensities is plotted against the
negative logarithmic p values of the t test. The dashed curve indicates the region of signiﬁcant interactions with a false discovery rate of 1%, and the
red dots in the upper right corners are the proteins that have the highest probability of interacting with VP24.
Journal of Proteome Research Article
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Validation of VP24-EGFP and EGFP-VP24 Interactions
Selected cellular targets identiﬁed in the immune-precipitations
to VP24 were then investigated using Western blot as an
alternative means of identiﬁcation (Figure 4A). These targets
included karyopherin α6 (as a positive control), ATP1A1,
lamin B1, and VDAC-1. The presence of STAT1 was also
investigated; even though it had not been identiﬁed in the
immunoprecipitation, as puriﬁed truncated STAT1 and puriﬁed
truncated VP24 had previously been shown to associate in
vitro.21 Whole cell lysate (input) and eluate (elution) from
separate immunoprecipitations were separated by 1D SDS-
PAGE; proteins were then transferred in Western blot and
detected using a primary antibody against each selected protein.
The data indicated that karyopherin α6, lamin B1, and ATP1A1
associated with both the EGFP-VP24 and VP24-EGFP
moieties. By Western blot, VDAC1 appeared to have a greater
association for EGFP-VP24 than VP24-EGFP. Although
STAT1 could be detected in the input fractions, it was not
detected in the immunoprecipitations (Figure 4A).
To further validate the mass spectrometry results and
potential interactions between VP24 and cellular proteins, we
performed reverse immunoprecipitations against selected
cellular targets where antibody combinations allowed. These
targets were karyopherin α6 (as a positive control) and lamin
B1. VP24-EGFP, EGFP-VP24, or EGFP were expressed in
293T cells and cell lysates were prepared. Immunoprecipita-
tions were performed using speciﬁc monoclonal antibodies
against karyopherin α6 and lamin B1. Analysis of the pull-down
products using a Western blot conﬁrmed the presence of
EGFP-VP24, VP24-EGFP, and EGFP in the input and elution
fraction. The presence of EGFP-VP24 and VP24-EGFP was
Figure 3. Map showing the group of proteins that interact with VP24:
(A) EGFP-VP24 and (B) VP24-EGFP using String 9.1 software. Most
of the proteins detected were located in the membranes and in the
perinuclear region, as is VP24. In the protein analysis, three main
proteins groups were detected: ribosome proteins, mitochondrial
proteins, and proteins related to the nucleus.
Figure 4. Validation of VP24-EGFP and EGFP-VP24 interactions by
Western blot analysis. (A) Conﬁrmation of proteins detected in the
label free mass spectrometry analysis by Western blot analysis was
done in the whole cell lysate or input sample (I) and in the eluate
sample (E) for the three diﬀerent expression constructs. Speciﬁc
monoclonal antibodies against karyopherin-α6, laminB-1, ATP1A1,
VDAC-1, and STAT-1 were used to the detection of the example
proteins. The antibody anti-EGFP was used as a control to show the
presence of the constructs EGFP-VP24 and VP24-EGFP in the input
and in the elution samples. (B) Validation of VP24-EGFP and EGFP-
VP4 interactions by reverse immunoprecipitations. To further validate
the mass spectrometry results, we performed reverse immunoprecipi-
tations against selected cellular proteins identiﬁed by the label-free
mass spectrometry analysis. The selected proteins for the validation of
the label-free mass spectrometry by using reverse immunoprecipita-
tions were karyopherin α6 and lamin B1; the presence of the protein
complex EGFP-VP24 and VP24-EGFP was conﬁrmed using a Western
blot analysis and using a speciﬁc antibody against EGFP.
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conﬁrmed using a speciﬁc antibody against EGFP (Figure 4B),
again validating the forward immunoprecipitations.
Inhibition of ATP1A1 in Ebola Virus Infected Cells
To investigate whether ATP1A1 played a functional role in
Ebola virus infected cells, we used the small molecule inhibitor
to ATP1A1, ouabain, to treat human MRC-5 cells infected with
EBOV strain ME718 (MOI = 0.1). This ﬁbroblast lung culture
was established from a 14-week gestation human male and is a
normal diploid cell line that supports the growth of Ebola virus
and has been used in antiviral drug screening studies.22 Cell
viability assays were used to determine the aﬀect of diﬀerent
Figure 5. Determining the eﬀect of the ATP1A1 inhibitor ouabain on Ebola virus infected cells. (A) An MTT assay was used to determine cell
viability in the absence of drug, the vehicle only control (DMSO), and various concentrations of ouabain and two controls using known small
molecule inhibitors that aﬀect the function of target cellular proteins (17-AAG and W-7). The data indicated that 10 and 20 nM ouabain and no
apparent eﬀect on cell viability compared with the untreated or vehicle only controls. (B) Stability of EGFP-VP24 and VP24-EGFP compared with
the EGFP control were assessed by Western blot in the absence and presence of various concentrations of ouabain. The abundance of GAPDH was
also determined. (C) qRT-PCR was used to compare the abundance of viral RNA in RNA puriﬁed from supernatant taken from cells infected with
Ebola virus at either 24 or 48 h postinfection in the absence (0 nM) or presence of ouabain (20 nM). The data were normalized to viral RNA levels
present in infected but untreated cells at 24 and 48 h postinfection.
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concentrations of ouabain on cell biology and included two
other small-molecule inhibitors (17-AAG and W-7) as positive
controls (Figure 5A). The data indicated that both 10 and 20
nM ouabain had no signiﬁcant eﬀect on cell viability compared
with either untreated or cells treated with the vehicle (DMSO)
only control. The 20 nM concentration of ouabain also had no
apparent eﬀect on the abundance of EGFP-VP24 in treated
cells expressing this construct (Figure 5B). Cells were either
infected and untreated or infected and treated with 20 nM
ouabain to determine the potential eﬀect of this drug on Ebola
virus infection. The experiment was repeated in triplicate, and
the use of a consistent volume of cell culture supernatant
permitted the comparison of the relative abundance of the
Ebola virus genome in the supernatant as a proxy measurement
for virus particles.23,24 Therefore, equal volumes of supernatant
containing progeny virus were taken at 24 and 48 h
postinfection. Viral RNA was then isolated and RNA levels
were compared in triplicate using qRT-PCR between each
treatment at 24 and 48 h post infection; data were normalized
to the level of viral RNA in infected but untreated cells (Figure
5C). Results indicated that infected cells treated with 20 nM
ouabain produced less viral RNA compared with infected but
untreated cells.
■ DISCUSSION
The genomes of RNA viruses have limited encoding capacity,
and therefore viral proteins usually possess multiple functions
in the cell and virus life cycle. The elucidation of these
interactions provides a better understanding of viral patho-
genesis and delivers more options for eﬀective antiviral
strategies. Ebola virus VP24 has been shown to have multiple
functions in the virus life cycle and therefore would be
predicted to interact with a variety of diﬀerent cellular proteins.
Several studies have investigated this with data suggesting that
VP24 can interact with karyopherin α, STAT1, and
Sec61α.10,21,25 In this study, aﬃnity tagging coupled to label-
free quantitative mass spectrometry was used to identify
potential interacting partners of VP24 and reduce or eliminate
false-positive interactions. Approximately 50 cellular proteins
were identiﬁed that had a high probability of interacting with
VP24. The majority of proteins identiﬁed associated with either
EGFP-VP24 or VP24-EGFP. However, some of the cellular
proteins identiﬁed were unique to the diﬀerent fusion proteins.
This may have been due some of the interactions with the
cellular proteins being sterically hindered by the EGFP moiety
and emphasized the advantage of using both the N- and C-
terminal tagged fusion proteins.
VP24 has aﬃnity for the plasma membrane and has also been
observed in the cytoplasm where the protein formed
cytoplasmic inclusions.26 These are the cellular locations of a
number of the proteins identiﬁed as associating with VP24
(Table 1). The reliability of this mass spectrometry data was
conﬁrmed using Western blot analysis and reverse immuno-
precipitations against selected cellular proteins. Furthermore,
the precipitations and mass spectrometry analysis were
repeated ﬁve times with independent samples to ensure the
reproducibility of the technique and also for the statistical
analysis. The immunoprecipitation technique was also opti-
mized for identifying low-aﬃnity and transient interactions by
modulating the salt concentration in the washing step.
Karypherin α subunit 6 (KPNA6) and 1 (KPNA1), identiﬁed
in this study with an average binding ratio of 8 to both EGFP-
VP24 and VP24-EGFP, reﬂected previous work demonstrating
an interaction between EBOV-VP24 and karypherin α subunit
6.8,10 In addition, as part of a larger viral/host protein study, the
interactome of VP24 was determined using tandem aﬃnity
puriﬁcation, and KPNA6 and other karypherins were identiﬁed
as part of 48 cellular proteins that potentially interacted with
VP24.27 Proteins in common with this previous work and
recorded in our analysis as having a greater than two-fold
abundance with either EGFP-VP24 or VP24-EGFP were
ANP32A, ANP32B, CCAR2 (KIAA1967), CGGBP1,
HNRNPL, HNRNPU, KPNA1, KPNA6, MYO5A,
POM121C, PRKCSH, RPS27, RPS27L, SLC25A3, TUB1C,
and TUBB, 28 proteins were not detected in our study, and
three proteins (EEF1A1, EEF1A2, and SPOP) were identiﬁed
as proteins that formed background/nonspeciﬁc interactions.
In the present study, no interaction was detected between
VP24 and STAT1 using the mass spectrometry approach, and
this was conﬁrmed by Western blot. Likewise, no interaction
between VP24 and STAT1 was described in the tandem aﬃnity
approach.27 This diﬀers from previously published work that
described an interaction between VP24 and STAT1.21
However, the diﬀerence in these results may be due to
diﬀerent systems employed. In the previously published work,
the interaction between EBOV VP24 and STAT1 was
determined by ELISA using puriﬁed truncated forms of VP24
and STAT1.21 In the present study, the EGFP moiety may have
prevented interaction with STAT1, likewise with the tandem
aﬃnity approach described previously,27 although the tag did
not prevent interaction with the karyopherins and other cellular
proteins.
Sec61α was not listed in the ﬁnal data set, but proteins that
form a complex with Sec61α were identiﬁed, including SSR4
and Sec61B. Notably, Sec61B has been formally demonstrated
to be signiﬁcant using biological approaches.25 Indeed, Sec61B
protein was found in one of the trial runs of this study but
excluded after the statistical analysis of the ﬁve independent
mass spectrometry analyses of EGFP-VP24 and VP24-EGFP.
This suggests that in the case of Sec61B our selection criteria
was too conservative or aﬀected by the EGFP moiety or the
interaction with Sec61α may be a weaker or more transient
interaction than those listed in Table 1. Although, we note that
the interaction between VP24 and Sec61α was identiﬁed using
a tandem tagging approach of VP2425 but was not identiﬁed in
a more recent study.27
One cellular protein with a high binding ratio was ATP1A1, a
Na+/K+-ATPase. The function of this protein is in establishing
and maintaining Na+ and K+ electrochemical gradients across
the plasma membrane and in cell signaling. Inhibiting the
function of ATP1A1 with ouabain resulted in a decrease in
progeny virus. Ouabain is used in treating atrial ﬁbrillation and
heart failure and has been demonstrated to have antiviral eﬀect
with other viruses including herpes simplex virus28 and porcine
reproductive and respiratory syndrome virus.29 The eﬀect of
ouabain on ATP1A1 may not have had a direct eﬀect on the
relationship between ATP1A1 and VP24. For example,
treatment of cells infected with human cytomegalovirus with
ouabain prevented enlargement of cells that is associated with
progeny virus production.30 Nevertheless, the use of this small
molecule to reduce progeny virus in Ebola-virus-infected cells
illustrates how existing therapeutics can be repurposed for
antiviral therapy. In the case of a natural infection in humans,
even a modest reduction in viral progeny production in vivo
may slow the virus suﬃciently for the host immune response to
mount a life-saving response.
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To our knowledge, this is the ﬁrst detailed interactome
analysis of VP24 using quantitative proteomics to identify
cellular proteins that have a high probability of interacting with
VP24 and to eliminate or identify cellular proteins that
potentially associate with a binding matrix used in immuno-
precipitations. The current study complements previous work
that used small molecules to inhibit the function of cellular
proteins to disrupt Ebola virus biology. For example, S-
adenosylhomocysteine hydrolase inhibitors were evaluated both
in vitro and in vivo and were detrimental to Ebola virus
infection.22 Inhibition of heat shock protein 90 using 17-AAG
disrupted Ebola biology in vitro31 At the time of publication of
this manuscript, the largest EBOV outbreak so far known is
occurring in West Africa and has proved diﬃcult to control; the
“repurposing” of therapeutics to reduce virus infection may tip
the balance between recovery and death.
Overall, the proteomic approach demonstrated how
determining the interactome of viral proteins can be used to
identify cellular proteins that play important roles in the virus
lifecycle and therefore increase the repertoire of potential
drugable targets. Resistance is a constant problem in developing
antiviral therapy to target the function of viral proteins.
Transiently targeting the function of host cell proteins crucial
to virus biology oﬀers an exciting new therapeutic avenue, with
the potential to solve the problem of resistance, as pro-viral
cellular proteins are evolutionarily static on the time scale of
lytic virus replication as well as separated from the genome that
would beneﬁt from resistance.
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